Ardelyx Amplified by first hyperphosphataemia success
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Incontinence failure puts Viveve under stress
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
Positive data Kalm Cara investors
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Reata’s big test approaches
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Myovant punished for success
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Roxadustat safety analysis provokes more questions than answers
Fibrogen tumbles on a confusing safety update for its most advanced project.
Astra makes machine learning bet with Benevolent AI deal
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
Go or no go? Novartis, Sanofi and Regeneron await US verdicts
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Boston and Coloplast sink on mesh mess
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.